作者
Robert J Motzer, Brian I Rini, David F McDermott, Osvaldo Arén Frontera, Hans J Hammers, Michael A Carducci, Pamela Salman, Bernard Escudier, Benoit Beuselinck, Asim Amin, Camillo Porta, Saby George, Victoria Neiman, Sergio Bracarda, Scott S Tykodi, Philippe Barthélémy, Raya Leibowitz-Amit, Elizabeth R Plimack, Sjoukje F Oosting, Bruce Redman, Bohuslav Melichar, Thomas Powles, Paul Nathan, Stéphane Oudard, David Pook, Toni K Choueiri, Frede Donskov, Marc-Oliver Grimm, Howard Gurney, Daniel YC Heng, Christian K Kollmannsberger, Michael R Harrison, Yoshihiko Tomita, Ignacio Duran, Viktor Grünwald, M Brent McHenry, Sabeen Mekan, Nizar M Tannir
发表日期
2019/10/1
期刊
The Lancet Oncology
卷号
20
期号
10
页码范围
1370-1385
出版商
Elsevier
简介
Background
In the ongoing phase 3 CheckMate 214 trial, nivolumab plus ipilimumab showed superior efficacy over sunitinib in patients with previously untreated intermediate-risk or poor-risk advanced renal cell carcinoma, with a manageable safety profile. In this study, we aimed to assess efficacy and safety after extended follow-up to inform the long-term clinical benefit of nivolumab plus ipilimumab versus sunitinib in this setting.
Methods
In the phase 3, randomised, controlled CheckMate 214 trial, patients aged 18 years and older with previously untreated, advanced, or metastatic histologically confirmed renal cell carcinoma with a clear-cell component were recruited from 175 hospitals and cancer centres in 28 countries. Patients were categorised by International Metastatic Renal Cell Carcinoma Database Consortium risk status into favourable-risk, intermediate-risk, and poor-risk subgroups and randomly …
学术搜索中的文章
RJ Motzer, BI Rini, DF McDermott, OA Frontera… - The Lancet Oncology, 2019
